Drug Overview
ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes. Samidorphan is a novel, potent mu-opioid antagonist, while olanzapine is an atypical antipsychotic with antagonist activity at the dopamine D2 and serotonin 5-HT2A receptors. ALKS 3831 was designed to display olanzapine’s high antipsychotic efficacy, while also benefitting from an improved metabolic profile. The drug is currently in Phase III development in the US, for the treatment of schizophrenia and bipolar disorder.
ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes. Samidorphan is a novel, potent mu-opioid antagonist, while olanzapine is an atypical antipsychotic with antagonist activity at the dopamine D2 and serotonin 5-HT2A receptors. ALKS 3831 was designed to display olanzapine’s high antipsychotic efficacy, while also benefitting from an improved metabolic profile. The drug is currently in Phase III development in the US, for the treatment of schizophrenia and bipolar disorder.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
ALKS 3831: Bipolar disorder
ALKS 3831: Schizophrenia
List of Figures
Figure 1: ALKS 3831 for bipolar disorder - SWOT analysis
Figure 2: ALKS 3831 for schizophrenia - SWOT analysis
Figure 3: Drug assessment summary of ALKS 3831 for schizophrenia
Figure 4: Drug assessment summary of ALKS 3831 for schizophrenia
Figure 5: ALKS 3831 sales for schizophrenia in the US, 2017-26
List of Tables
Table 1: ALKS 3831 drug profile
Table 2: ALKS 3831 Phase III trials in bipolar disorder
Table 3: ALKS 3831 drug profile
Table 4: ALKS 3831 Phase III data in schizophrenia
Table 5: ALKS 3831 Phase III trials in schizophrenia
Table 6: ALKS 3831 sales for schizophrenia in the US ($m), 2017-26
